Published in Life Sci on January 01, 1979
Regulation by secretin, vasoactive intestinal peptide, and somatostatin of cyclic AMP accumulation in cultured brain cells. Proc Natl Acad Sci U S A (1980) 0.92
Functional role for vasoactive intestinal polypeptide in the caudate nucleus: a 2-deoxy[14C]glucose investigation. Proc Natl Acad Sci U S A (1983) 0.75
Vasoactive intestinal polypeptide immunoreactivity in the human cerebellum: qualitative and quantitative analyses. J Anat (2009) 0.75
Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression. Psychopharmacology (Berl) (2011) 0.75
The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med (1995) 4.61
Polypeptide with broad biological activity: isolation from small intestine. Science (1970) 4.14
Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA (1996) 4.13
Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci (1982) 3.02
Lower efficacy: interaction with an inhibitory receptor or partial agonism? Trends Pharmacol Sci (1994) 2.81
Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur J Biochem (1972) 2.59
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev (1998) 2.30
Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors. N Engl J Med (1975) 2.30
Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal mucosa. J Clin Invest (1974) 2.28
Hybrid test bench for evaluation of any device related to mechanical cardiac assistance. Int J Artif Organs (2005) 2.05
Vasoactive intestinal peptide: a possible transmitter of nonadrenergic relaxation of guinea pig airways. Science (1980) 2.01
Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol (1993) 1.92
VIP as a possible neurotransmitter of non-cholinergic non-adrenergic inhibitory neurones. Nature (1980) 1.87
Cardioselective profile of AF-DX 116, a muscarine M2 receptor antagonist. Life Sci (1986) 1.80
Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. Science (1976) 1.76
Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res (1981) 1.74
Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. Eur J Biochem (1974) 1.71
Biological activities of synthetic peptides corresponding to fragments of and to the entire sequence of the vasoactive intestinal peptide. Proc Natl Acad Sci U S A (1973) 1.67
Effects on smooth muscle preparations of unidentified vasoactiv peptides from intestine and lung. Nature (1970) 1.51
Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. J Am Coll Cardiol (2000) 1.40
Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature (1978) 1.35
Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature (1970) 1.30
Competitive antagonists discriminate between NK2 tachykinin receptor subtypes. Br J Pharmacol (1990) 1.26
The activity of peptides of the endothelin family in various mammalian smooth muscle preparations. Eur J Pharmacol (1989) 1.24
In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376. J Pharmacol Exp Ther (1991) 1.24
Occurrence of vasoactive intestinal polypeptide (VIP)-like immunoreactivity in certain cholinergic neurons of the cat: evidence from combined immunohistochemistry and acetylcholinesterase staining. Neuroscience (1979) 1.23
Hyperglycemic and glycogenolytic effects of vasoactive intestinal polypeptide. Proc Soc Exp Biol Med (1973) 1.22
VAMPIRE: Vessel assessment and measurement platform for images of the REtina. Conf Proc IEEE Eng Med Biol Soc (2011) 1.21
Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. Am Rev Respir Dis (1984) 1.19
The C-terminal hexapeptide, endothelin-(16-21), discriminates between different endothelin receptors. Eur J Pharmacol (1989) 1.17
Vasoactive intestinal polypeptide in brain: localization in and release from isolated nerve terminals. Proc Natl Acad Sci U S A (1977) 1.16
A potent and selective agonist for NK-2 tachykinin receptor. Peptides (1989) 1.14
Vasoactive intestinal peptide as a neural mediator of gastric relaxation. Am J Physiol (1985) 1.14
Solubilization and separation of the glucagon receptor and adenylate cyclase in guanine nucleotide-sensitive states. J Biol Chem (1977) 1.14
Vasoactive intestinal polypoptide: inactivation in liver and potentiation in lung of anesthetized dogs (384699). Proc Soc Exp Biol Med (1975) 1.14
Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Pharmacol Ther Toxicol (1989) 1.13
Stimulation of insulin and glucagon secretion by vasoactive intestinal peptide. Am J Physiol (1977) 1.13
Analogue chromatic continuous scale (ACCS): a new method for pain assessment. Clin Exp Rheumatol (1985) 1.11
Activation by bacterial lipopolysaccharide causes changes in the cytosolic free calcium concentration in single peritoneal macrophages. J Immunol (1991) 1.11
Observed prevalence of tick-borne pathogens in domestic animals in Sicily, Italy during 2003-2005. Zoonoses Public Health (2007) 1.11
Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J (2008) 1.09
New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res (1996) 1.09
Predictors of stable hypertension in young borderline subjects: a five-year follow-up study. J Cardiovasc Pharmacol (1986) 1.09
VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. Am J Physiol (1995) 1.07
Vasoactive intestinal polypeptide (VIP): current status. Peptides (1984) 1.06
Vasoactive intestinal polypeptide excitation of central neurons. Can J Physiol Pharmacol (1978) 1.06
Effect of VIP infusion in water and ion transport in the human jejunum. Gastroenterology (1980) 1.06
Anxiety and depressive disorders in an emergency department ward of a general hospital: a control study. Emerg Med J (2004) 1.05
Distribution of enteric nerve cell bodies and axons showing immunoreactivity for vasoactive intestinal polypeptide in the guinea-pig intestine. Neuroscience (1980) 1.04
Binding and functional characterization of the cardioselective muscarinic antagonist methoctramine. J Pharmacol Exp Ther (1988) 1.03
Production of leukotrienes in a model of focal cerebral ischaemia in the rat. Br J Pharmacol (2001) 1.03
Studies in vitro of amine uptake mechanisms in heart. Biochem Pharmacol (1966) 1.03
Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci (2014) 1.02
Early detection of hypersensitivity pneumonitis in office workers. Am J Med (1978) 1.02
Vasoactive intestinal peptide and its relationship to ganglion cell differentiation in neuroblastic tumors. Lab Invest (1979) 1.01
AF-DX 116, a cardioselective muscarinic antagonist. J Pharmacol Exp Ther (1987) 1.00
Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro. Am Rev Respir Dis (1981) 0.99
A highly selective NK-2 tachykinin receptor antagonist containing D-tryptophan. Eur J Pharmacol (1990) 0.99
Vasoactive intestinal peptide. J Endocrinol Invest (1986) 0.99
Nitric oxide as a mediator of oxidant lung injury due to paraquat. Proc Natl Acad Sci U S A (1994) 0.99
Metabolic functions of the pulmonary circulation. Circ Res (1982) 0.99
Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema. A preliminary report. Bull Eur Physiopathol Respir (1983) 0.98
Simultaneous recording of vesical and urethral pressure in urethane-anesthetized rats: effect of neuromuscular blocking agents on the activity of the external urethral sphincter. J Pharmacol Methods (1991) 0.98
Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J Pharmacol (1986) 0.98
Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins. Physiol Rev (1995) 0.97
Humoral control of airways. Ann N Y Acad Sci (1974) 0.97
Effect of synthetic tachykinin analogues on airway microvascular leakage in rats and guinea-pigs: evidence for the involvement of NK-1 receptors. J Auton Pharmacol (1991) 0.97
(Imidazolylphenyl)formamidines. A structurally novel class of potent histamine H2 receptor antagonists. J Med Chem (1984) 0.97
Systemic hypotension and the development of acute sensorineural hearing loss in young healthy subjects. Arch Otolaryngol Head Neck Surg (2001) 0.96
In vivo and in vitro pharmacology of SR 48,968, a non-peptide tachykinin NK2 receptor antagonist. Eur J Pharmacol (1993) 0.96
Comparison of tachykinin NK1 and NK2 receptors in the circular muscle of the guinea-pig ileum and proximal colon. Br J Pharmacol (1994) 0.96
Further evidence for the existence of NK2 tachykinin receptor subtypes. Br J Pharmacol (1991) 0.96
Vasoactive intestinal polypeptide (VIP) in mouse and rat brain: an immunocytochemical study. Brain Res (1980) 0.95
Vasoactive intestinal peptide. Relaxant neurotransmitter in tenia coli of the guinea pig. Gastroenterology (1985) 0.95
Tachykinin receptors in the guinea-pig renal pelvis: activation by exogenous and endogenous tachykinins. Br J Pharmacol (1992) 0.95
Characterization of the Ca2+ responses evoked by ATP and other nucleotides in mammalian brain astrocytes. Br J Pharmacol (1997) 0.95
Dactylitis in patients with seronegative spondylarthropathy. Assessment by ultrasonography and magnetic resonance imaging. Arthritis Rheum (1996) 0.95
Circulating levels of vasoactive intestinal polypeptide in liver disease. Arch Intern Med (1979) 0.94
Tachykinin antagonists inhibit nerve-mediated contractions in the circular muscle of the human ileum. Involvement of neurokinin-2 receptors. Gastroenterology (1992) 0.94
The role of histamine H1- and H2-receptors in the generation of thromboxane A2 in perfused guinea-pig lungs. Br J Pharmacol (1979) 0.94
High-performance liquid chromatographic determination of ribavirin in serum and urine and of its urinary metabolite 1,2,4-triazole-3-carboxamide. J Chromatogr (1987) 0.93
Regulation of apoptosis by vasoactive peptides. Am J Physiol Lung Cell Mol Physiol (2001) 0.93
Relationship of spasmogenic and smooth muscle relaxant peptides from normal lung to other vasoactive compounds. Nature (1977) 0.93
Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br J Cancer (2012) 0.93
Pulmonary alveolar hypoxia: release of prostaglandins and other humoral mediators. Science (1974) 0.93
Mechanism of action of vasoactive intestinal polypeptide on cerebral arterioles. Am J Physiol (1980) 0.92
Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. J Hum Hypertens (2010) 0.92
Correlation between release of free arachidonic acid and prostaglandin formation in brain cortex and cerebellum. Prostaglandins (1976) 0.92
FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium. Cell Death Differ (2006) 0.91
The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes. Prostaglandins (1984) 0.91
Vasoactive intestinal peptide: evidence for a hypothalamic site of action to release growth hormone, luteinizing hormone, and prolactin in conscious ovariectomized rats. Endocrinology (1979) 0.91
Pulmonary lipid composition of species with and without surfactant. Am J Physiol (1966) 0.91
Vasoactive intestinal polypeptide in brain synaptosomes. Lancet (1976) 0.91
Tachykinins and reflexly evoked atropine-resistant motility in the guinea pig colon in vivo. J Pharmacol Exp Ther (1993) 0.91
(5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br J Pharmacol (1987) 0.91
Extra-vesicular binding of noradrenaline and guanethidine in the adrenergic neurones of the rat heart: a proposed site of action of adrenergic neurone blocking agents. Br J Pharmacol (1976) 0.91